Welcome to our dedicated page for MBX Biosciences news (Ticker: MBX), a resource for investors and traders seeking the latest updates and insights on MBX Biosciences stock.
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in June 2025. CEO Kent Hawryluk will present at the Jefferies Global Healthcare Conference in New York on June 4 at 2:00 p.m. ET, and at the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET. Live webcasts will be available on the company's investor website, with replays accessible for approximately 90 days after the events.
- Phase 2 Avail trial for canvuparatide in hypoparathyroidism completed enrollment with 64 participants, with topline results expected in Q3 2025
- IND submission for MBX 4291, a once-monthly GLP-1/GIP co-agonist prodrug for obesity treatment, planned for Q2 2025
- Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia to begin in H2 2025
Financial results show R&D expenses increased to $22.4 million (vs $11.0M in Q1 2024), G&A expenses rose to $4.1 million (vs $2.3M), with a net loss of $23.9 million (vs $12.3M).
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in May 2025.
The company's President and CEO, Kent Hawryluk, will present at the Citizens Life Sciences Conference on May 7, 2025 (3:00-3:25 p.m. ET) and the RBC 2025 Global Healthcare Conference on May 21, 2025 (3:35-4:00 p.m. ET). Both events will be held in New York and will feature fireside chats along with one-on-one meetings.
Investors can access live webcasts of both presentations through the company's website at investors.mbxbio.com/news-events/events. Replay recordings will be available approximately two hours after each event and remain accessible for 90 days.
MBX Biosciences (Nasdaq: MBX) has appointed Steve Hoerter as an independent director to its Board of Directors. Hoerter brings over 30 years of pharmaceutical commercialization and executive leadership experience to the clinical-stage biopharmaceutical company.
Most recently, Hoerter served as President, CEO and Director of Deciphera Pharmaceuticals until its $2.4 billion acquisition by Ono Pharmaceutical in 2024. His previous roles include senior commercial leadership positions at Agios Pharmaceuticals, Clovis Oncology, Roche, and Genentech.
The appointment aims to support MBX's advancement of its pipeline focused on endocrine and metabolic disorders, including programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company leverages its Precision Endocrine Peptides™ technology platform.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Kent Hawryluk, will deliver a podium presentation on Monday, April 7, 2025, from 8:00 a.m. to 8:40 a.m. ET. The presentation will be accompanied by one-on-one meetings.
Investors can access the live webcast through the investors section of MBX Biosciences' website at investors.mbxbio.com/news-events/events. A replay will be available approximately two hours after the event and will remain accessible for about 90 days on the company's website.
MBX Biosciences (Nasdaq: MBX) has announced its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company completed enrollment of 64 patients in its Phase 2 Avail™ trial of canvuparatide for hypoparathyroidism, with topline results expected in Q3 2025.
Key developments include positive Phase 1 results for MBX 1416 in post-bariatric hypoglycemia, with Phase 2 trials planned for 2H 2025. The company is also preparing an IND submission for MBX 4291, their obesity treatment candidate, in Q2 2025.
Financial highlights:
- Cash position: $262.1M as of December 31, 2024
- R&D expenses: $57.4M for 2024 (up from $28.5M in 2023)
- G&A expenses: $10.8M for 2024 (up from $6.8M in 2023)
- Net loss: $61.9M for 2024 (increased from $32.6M in 2023)
MBX Biosciences (Nasdaq: MBX) has strengthened its leadership team with two key appointments. Chatan Charan, Ph.D. joins as Senior Vice President of Pharmaceutical Development and CMC, bringing over 30 years of drug development experience, including his recent role at Harpoon Therapeutics where he contributed to its sale to Merck Pharmaceuticals.
Mark Hope has been appointed Senior Vice President of Regulatory and Quality, with three decades of regulatory expertise. He previously served at Cerevel Therapeutics, supporting its acquisition by AbbVie Inc. Both executives will support MBX's development of precision peptide therapies for endocrine and metabolic disorders.